| MATERIALS AND METHODS

| Data collection
Medical records of all cats that received an RBC transfusion with or without a major crossmatch or had a major crossmatch performed without subsequent RBC administration at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania from January 1, 2013, to December 31, 2016, were reviewed retrospectively. Our institution's clinical laboratory feline crossmatch logbook and blood bank transfusion logbook were reviewed to identify cats for this study. Cats were excluded if the medical record was missing or incomplete.
The following information was recorded: signalment, blood type, transfusion history, major and minor crossmatch results, RBC product administered (pRBCs or fresh whole blood [FWB] 
| Blood donors
Feline pRBCs and FWB were obtained primarily from our institution's blood bank. During times of increased demand or shortage of blood products, pRBCs were purchased from a commercial animal blood bank (Animal Blood Resources International). Our institution's donor cats were owned by students or hospital staff or maintained in the hospital colony. Donor health screening included history, physical examination, and blood hemoglobin concentration performed before each donation, and an annual CBC, serum biochemistry panel, and testing for blood-borne pathogens, as outlined in the updated consensus statement of American College of Veterinary Internal Medicine. 14 
| Transfusions and patient monitoring
The decision to administer an RBC transfusion was at the discretion of the primary clinician. The main cause of anemia was classified as blood loss, hemolysis, or ineffective erythropoiesis. The pretransfusion PCV was defined as that measured closest to the start of the RBC transfusion. The posttransfusion PCV was defined as that recorded closest to the end of the RBC transfusion, typically within 1-2 hours posttransfusion. The change in PCV, hereafter referred to as ΔPCV, was calculated as the difference between the posttransfusion and pretransfusion PCV. Patients were monitored during the transfusion by a standard protocol that includes evaluating vital parameters, mucous membrane color, pulse quality, blood pressure, and mentation every 15 minutes during the transfusion. A febrile transfusion reaction was defined as an increase in body temperature ≥ 2 F during or within 4 hours posttransfusion if active rewarming was not used. An acute hemolytic transfusion reaction was defined as a development of fever, hemoglobinuria, hemoglobinemia, and a lack of increase in PCV For a small subset of cats, a crossmatch was performed using both the tube method and the gel column method, as previously described, 12 in a prospective comparison of these procedures. Gel crossmatches were performed by a single experienced laboratory technician who was not blinded to results of the tube crossmatch.
Degree of RBC retention in gel corresponded to degree of incompatibility: 4+, all RBCs at the top of the gel; 3+, RBC agglutinates throughout and on top of gel; 2+, RBC agglutinates dispersed throughout the gel; and 1+, few RBC agglutinates in the lower half of the gel but most
RBCs at the bottom of the gel. For a compatible crossmatch, all RBCs were at the bottom of the gel column.
| Statistical analysis
Statistical analyses were performed using standard statistical software for which a crossmatch was performed (3 of 157 cats), compatibility data were not available because of autoagglutination (n = 1) or insufficient information recorded during after-hours testing (n = 2). Of the 55 cats previously transfused, 15 cats (27%) were incompatible (1+ to 2+) on the major crossmatch to ≥1 donor (Table 1) , significantly more than in the transfusion-naive group (P = 0.042). In addition, 2 cats with unknown transfusion history had an incompatibility (1+ to 2+) on the major crossmatch. All of the incompatibility reactions observed on both major and minor crossmatches were manifested as agglutination;
hemolysis was not reported for any crossmatch.
Eleven cats had minor crossmatch incompatibilities (1+ to 2+) to ≥1 donor, with 6 of these cats (4 transfusion-naive and 2 previously transfused) also having major crossmatch incompatibilities ( Table 2 ).
The 5 cats with minor incompatibility only all were transfusion-naive.
Thirteen feline blood donors were involved with these minor incompatibilities. During the 4-year study period, the number of minor crossmatches performed using plasma from each of these 13 donors ranged from 1 to 19 (median, 7), with plasma from only 1 donor responsible for causing a minor incompatibility in >1 cat. Plasma from this donor was used in minor crossmatches for 19 cats but produced an incompatibility reaction in only 2 cats.
| Influence of storage time of donor RBC sample on major crossmatch compatibility
With major crossmatches performed for 212 cats, most cats crossmatched to >1 donor, and 51 cats having subsequent crossmatches performed during the study period, 683 major crossmatches were performed. Results were available for 674 crossmatches; compatibility could not be determined in 9 crossmatches because of RBC autoagglutination. There were 586-compatible and 88-noncompatible major crossmatches. Donor RBC samples used for compatibility testing for renal transplantation screening were fresh, with the crossmatch performed the same day as sample collection. There were 498 donor RBC samples stored for less than 10 days ("fresh"), with 65 (13%) major crossmatch incompatibilities noted, and 176 donor RBC samples stored for more than 10 days ("old"), with 23 (13%) major crossmatch incompatibilities, with no difference between groups (P = 0.996). Furthermore, no difference was observed in degree of major crossmatch incompatibility when comparing fresh and old donor RBC samples (P = 0.412).
| RBC transfusion characteristics and influence of crossmatch on outcome
Red blood cell transfusions were administered to 249 cats for anemia because of ineffective erythropoiesis (n = 118), blood loss (n = 118), and hemolysis (n = 13). The majority of cats (n = 235) received pRBCs For the first pRBC transfusion, the median pretransfusion PCV (n = 243) was 15% (range, 5%-40%), with no difference between cats with (PCV, 15.5%) and without (PCV, 15%) a crossmatch performed (P = 0.19). The median volume of pRBCs administered during the first transfusion was 5.3 mL/kg (range, 2.4-18 mL/kg), with a median of 5.1 mL/kg for cats without a crossmatch and 5.4 mL/kg for cats with a crossmatch, also with no difference between groups (P = 0.704).
The median posttransfusion PCV (n = 231) was 20% (range, 10%-55%) and ΔPCV was +5% (range, −17% to +21%). For cats that did not have a pretransfusion crossmatch performed, the median ΔPCV (n = 77) was +6% (range, −5% to +21%), whereas the median ΔPCV (n = 154) for cats that had a pretransfusion crossmatch performed was +5% (range, −17% to +14%) (P = 0.019). The median ΔPCV scaled to the dose of pRBCs administered was +0.8%/mL/kg (range, −1.7 to +5.25%/mL/kg). For cats that did not have a pretransfusion crossmatch performed, the median scaled ΔPCV was +0.97%/mL/kg (range, −1.56 to +5.25%/mL/kg), whereas the median scaled ΔPCV for cats that had a pretransfusion crossmatch performed was +0.76%/ mL/kg (range, −1.7 to +5.18%/mL/kg; P = 0.042). Cause of anemia did not influence ΔPCV. The median total volume of pRBCs administered during hospitalization was 6.5 mL/kg (range, 2.4-38.5 mL/kg).
For cats that did not have a pretransfusion crossmatch performed, the median total volume of pRBCs administered was 5.7 mL/kg (range, 2.5-26.4 mL/kg), whereas the median total volume of pRBCs administered to cats that had a pretransfusion crossmatch performed was 6.7 mL/kg (range, 2.4-38.5 mL/kg; P = 0.04).
Transfusion monitoring data associated with the first pRBC transfusion were available for 240 cats. Twelve cats (5%) developed fever, without evidence of hemolysis, during the transfusion, occurring more often in cats that received typed, non-crossmatched pRBCs (8 of 79;
10.1%) than in cats given crossmatch-compatible pRBCs (4 of 161;
2.5%; P = 0.022). In addition, 2 cats developed suspected transfusionassociated adverse events; neither had a pretransfusion crossmatch performed. One cat received a pRBC transfusion for blood loss anemia secondary to severe flea infestation and experienced respiratory followed by cardiac arrest 36 hours later. Transfusion-associated lung injury or pulmonary thromboembolism was suspected by the primary clinician. The second cat received pRBCs at the start of a hemodialysis procedure for lily toxicity, partially dislodged its dialysis catheter during treatment, and then experienced cardiopulmonary arrest. After resuscitation, hemoglobinuria, hyperbilirubinemia, and a lack of increase in PCV were noted. Post-event crossmatching to investigate the possibility of RBC alloantibodies leading to an acute hemolytic transfusion reaction was not performed. Necropsy was declined in both cases.
Of the 246 cats that received pRBC transfusions, 188 (76.4%) survived to hospital discharge. A pretransfusion crossmatch was not associated with improved survival to discharge (P = 0.15) or 30 (P = 0.208) or 60 (P = 0.052) days posttransfusion. In addition, there was no difference in euthanasia (P = 0.191) or in-hospital death (P = 0.6) between cats that received crossmatched as compared to non-crossmatched pRBCs.
| Development of non-AB incompatibilities posttransfusion
During the study period, 43 cats had a crossmatch performed within 1-15 days after the initial pRBC transfusion in preparation for a second transfusion. Some degree of incompatibility (1+ to 3+) was observed on the major crossmatch for 11 cats (25.6%), and 7 of these cats (16.3%) had no incompatibility on their first crossmatch to 2 or 3 donors tested. Four of these 7 cats developed an incompatibility to the same donors to which they previously had been compatible, and 
| Administration of type-matched, crossmatchincompatible pRBCs
Six cats, 5 of which had been transfused previously, were crossmatchincompatible to all pRBC units tested (3 units, n = 4; 4 units, n = 1;
2 units, n = 1) and were given the least incompatible unit. Five cats received pRBCs to which there was a 1+ major incompatibility, and 1 cat was given a pRBC unit to which there was a 1+ minor incompatibility. None of these cats developed an obvious febrile or acute hemolytic transfusion reaction, although 4 of 6 cats received the pRBC unit as a hemodialysis prime, which complicated transfusion monitoring.
The median ΔPCV was +4% (range, +1% to +13%), and the median scaled ΔPCV was +0.86%/mL/kg (range, +0.19 to +2%/mL/kg). The 2 non-dialysis cats, 1 with a minor and 1 with a major RBC incompatibility, survived to >60 days posttransfusion. Of the 4 cats that underwent hemodialysis, 1 cat being treated for a massive overdose of vincristine died in the hospital 2 days posttransfusion, 2 cats were discharged but survived <30 days, and 1 cat survived >60 days posttransfusion.
| Comparison of tube and gel column crossmatch
Blood crossmatches were performed using both the tube and gel col- than Mik. In a prospective, randomized, controlled study of 48 transfusion-naive cats in the United States, 24 cats had a pretransfusion crossmatch performed, with 7 cats (29%) incompatible to ≥1 typespecific pRBC unit. 15 In a study evaluating transfusion practices in cats during a 3-year period at a university teaching hospital in Germany, pretransfusion crossmatching of 60 cats identified a major crossmatch (non-AB blood type) incompatibility in 1 transfusion-naive cat. 16 Crossmatch screening of 112 cats in the United Kingdom failed to detect any non-AB blood type incompatibilities. 17 In a study of 20 hospitalized cats in Germany undergoing serial crossmatching to detect alloimmunization to transfused RBCs, major crossmatch incompatibility was not found in any transfusion-naive cats. 18 The reason for the higher prevalence of non-AB blood-type incompatibilities in transfusion-naive cats in our and another US study 15 Development of RBC alloantibodies posttransfusion is an anticipated event across many species and is the basis for the long-standing recommendation to perform a blood crossmatch for recipients given a blood transfusion ≥4 days before the planned transfusion, but, to our knowledge, data to support this specific recommendation for cats are lacking. The prevalence of non-AB RBC incompatibilities in previously transfused cats has been reported to be approximately 25%. 13, 18 Pretransfusion screening of 43 cats, most of which were known to have been transfused >3 days previously, identified 11 cats (25.6%) with major crossmatch incompatibility to ≥1 pRBC unit. 13 Similarly, 5 of 20 (25%) cats, all transfusion-naive, with a pretransfusion-compatible crossmatch were documented to have a major crossmatch incompatibility developed 2-10 days (median, 5 days) after receiving ABcompatible whole blood. 18 In our study, 15 of 55 (27%) previously transfused cats had major crossmatch incompatibilities, 11 cats with 1 + incompatibility and 4 cats with 2+ incompatibility. Forty-three of 214 cats had a second crossmatch performed 1-15 days after the initial transfusion during the study period, with 10 cats (23%) having a 1 + to 3+ major crossmatch incompatibility, including 6 cats that were previously compatible to 2-3 donors tested. Four of 6 cats developed an incompatibility to donors to which they were previously compatible; 3 of the 4 cats had received only 1 pRBC transfusion, and the time to detection of incompatibility was 2-3 days, similar to the previously cited prospective study. 18 Although our study was not designed to evaluate time to alloimmunization posttransfusion, the finding of non-AB RBC incompatibilities in cats as early as 2 days after transfusion in 2 studies warrants reconsideration of the general guideline to perform a crossmatch ≥4 days after an initial blood transfusion.
Minor crossmatch incompatibilities are considered less clinically relevant than major crossmatch incompatibilities with regard to recipient safety and transfusion efficacy, particularly with pRBC transfusions in which a negligible amount of donor plasma is administered.
Nevertheless, the finding of plasma from 13 donor cats, none of which had ever received a blood transfusion, resulting in minor crossmatch incompatibilities with 11 recipient cats suggests that these donors had naturally occurring non-AB RBC alloantibodies. Although plasma from the 13 donors was used in minor crossmatches for multiple recipients (median, 7; range, 1-19), only plasma from 1 donor resulted in a minor incompatibility with >1 recipient, with the donor used for 19 crossmatches being incompatible with 2 recipients. Therefore, none of the donors likely had naturally occurring antibodies to a common RBC antigen, such as Mik.
In a previous retrospective study evaluating the influence of crossmatch on posttransfusion PCV in cats, administration of typespecific, crossmatch-compatible pRBC transfusions was associated with a significantly greater increase in PCV (scaled to the dose of pRBCs administered, +1.02 AE 0.51%/mL/kg) when compared to administration of typed, non-crossmatched pRBCs (+0.75 AE 0.65%/ mL/kg) 13 but, the clinical relevance of this finding is uncertain. A subsequent prospective study evaluating the change in PCV (scaled to the dose of pRBCs) at 4 time points posttransfusion did not detect a difference between cats with (+0.60 AE 0.66%/mL/kg at 1 hour posttransfusion) and without (+0.74 AE 0.53%/mL/kg at 1 hour posttransfusion; P = 0.43) a pretransfusion crossmatch. 15 Similarly, in our study, cats receiving crossmatch-compatible pRBCs did not have a greater increase in PCV posttransfusion compared to cats without a pretransfusion crossmatch. Rather, statistical analysis indicated that cats receiving pRBCs without a pretransfusion crossmatch had a greater increase in median scaled ΔPCV (+0.97%/mL/kg) compared to cats with a crossmatch (+0.76%/mL/kg), a finding for which no logical explanation is apparent. Many factors other than crossmatch results can influence ΔPCV, including ongoing patient blood loss or hemolysis, concurrent administration of other fluids, and timing of posttransfusion PCV. In our retrospective study, we could not control for these variables, but there was no significant difference in ΔPCV between cats with blood loss or hemolysis compared to other causes of anemia.
However, in the prospective study, 15 The frequency of adverse events associated with RBC transfusions in cats has been reported to range from 1.2% to 20.8%, with febrile transfusion reactions being most common. 15, 16, 19, 20 there is no obvious explanation for the finding of febrile reactions occurring more often in cats that were not crossmatched. In a prospective study of transfusion-naive cats, no significant difference was found in the incidence of febrile, nonhemolytic transfusion reactions between cats with (3 of 24; 13%) and without (7 of 24; 29%) a pretransfusion crossmatch. 15 Two other cats in our study that received non-crossmatched pRBCs were suspected to have transfusionassociated adverse events (one of which could have been an acute hemolytic transfusion reaction) and died, but neither necropsy nor posttransfusion compatibility testing was performed for either cat.
Given the variability in degree of patient monitoring during and after transfusions, the recipient's underlying condition (eg, hemolytic anemia, hepatobiliary disease), as well as the potential impact of general anesthesia, surgery, and hemodialysis on recipient parameters evaluated, it is possible that transfusion-associated adverse events were under-recognized in our study. Likewise, some of the febrile reactions could have been a consequence of the patient's underlying disease process rather representing a transfusion-associated adverse event, but this would have been the case for both cats with and without a pretransfusion crossmatch.
In a situation in which a recipient cat is in need of oxygen-carrying support but is crossmatch-incompatible to all donors tested, veterinarians typically select the least incompatible RBC unit, but the safety and efficacy of such a transfusion is uncertain. In a study in which crossmatch testing was performed after whole blood transfusions had already been given, blood had been administered to 5 cats (receiving 7 transfusions) despite incompatible major crossmatch results (ranging from microscopic 1+ to macroscopic 3+ agglutination), with no obvious clinical transfusion reactions noted in any of the cats and with an increase in hematocrit noted after 5 of 7 transfusions. 16 In our study, 5 previously transfused cats were incompatible on the major crossmatch to all donors tested and received pRBC units to which there was a 1+ incompatibility. Although no obvious adverse events were noted, 4 of the 5 cats received the pRBC unit as a hemodialysis prime, complicating monitoring. The median ΔPCV was +4% (median scaled ΔPCV of +0.86%/mL/kg), suggesting that the transfused RBCs were not immediately lysed or removed from the circulation. It is not possible to conclude from our study that administration of feline RBC units to which there is a 1+ major incompatibility will be a safe and efficacious transfusion.
Several blood crossmatch techniques have been used to evaluate RBC compatibility in cats: tube method, 12, 13, 22 gel column method, 12 and microtitration system. 17 In a comparison of crossmatch results using the tube and gel methods for a feline renal transplant recipient with anti-Mik alloantibodies, there was an agreement between the 2 methods in identifying 3 incompatible donors and 2 compatible donors, but the grading of agglutination tended to be higher using the gel method (3+) as compared to the tube method (weak to 2+). 12 Similarly, a comparison of the tube and gel methods for evaluation of RBC compatibility in horses indicated a high correlation between results of the 2 methods. 23 In our study, a prospective comparison of crossmatch results of the tube and gel methods for 10 recipient cats A study evaluating the effect of blood storage time on crossmatching in horses documented that donor RBC samples stored for 1-4 weeks resulted in a higher number of major incompatibility agglutination reactions compared to fresh RBC samples. 24 For practical purposes, in small animal transfusion medicine, the storage time of the donor RBC sample is the same as the duration of storage of the pRBC unit. Our study was not designed specifically to evaluate the effect of storage time of donor RBC samples on crossmatching in cats, but we did not detect an association between duration of RBC storage and major crossmatch incompatibilities. The pRBC unit stored for 40 days (which is beyond the recommended storage time) was an anomaly caused by incorrect calculation of the collection date for a unit purchased from a commercial animal blood bank. Nonetheless, a major crossmatch to this aged pRBC unit was compatible, but the unit was not administered. 
